Merck’s Four-Week Hepatitis C Regimen Fails to Top Gilead

November 10, 2014 12:00 AM

1 0

Merck & Co. (MRK:US) won’t move forward with an ultra-short hepatitis C regimen that attempted to cut treatment durations in half by combining two of its drugs with another from Gilead Sciences Inc.

Patients in the mid-stage, 102-person trial got Merck’s experimental drugs grazoprevir and elbasvir, along with Gilead’s Sovaldi, for as little as four weeks, with the length of treatment based partly on how severe their infection was.

Also read: BAT heaps $47 bln of peer pressure on Reynolds

Read more

To category page